Shared on 15 Aug 25

Analysts maintain a cautious stance on Quanterix due to near-term uncertainty, weak Q2 results, and biopharma sector headwinds, keeping the price target unchanged at $6.00. Analyst Commentary Downgrade reflects a lack of near-term visibility and absence of clear catalysts to drive the stock higher.

Read more

0 votesShare

Shared on 01 May 25

Fair value Decreased 53%

Read more

0 votesShare

Shared on 24 Apr 25

Fair value Decreased 5.45%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Read more

0 votesShare

Shared on 17 Apr 25

Fair value Decreased 4.30%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Read more

0 votesShare

Shared on 09 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Read more

0 votesShare

Shared on 02 Apr 25

Fair value Increased 26%

AnalystConsensusTarget has increased revenue growth from 8.3% to 11.3%, increased future PE multiple from 23.2x to 29.0x and increased shares outstanding growth rate from 0.0% to 0.0%.

Read more

0 votesShare